Literature DB >> 1826826

Thy 1+ asialo GM1+ dendritic epidermal cells in skin defense mechanisms of vaccinia virus-infected mice.

S Ikeda1, T Tominaga, C Nishimura.   

Abstract

To define different growths of vaccinia virus (VV) in the footpad, ear and tail skin of ddY and BALB c mice, we investigated the roles of Ia+ Langerhans cells (LC) and Ia- dendritic epidermal cells (DEC) in the skin defense mechanisms. With respect to LC obtained from the footpad, ear and tail skin of BALB/c mice, the level of lysosomal enzyme, phagocytic, antigen-presenting and antiviral activities were almost the same. Footpad DEC exhibited higher natural killer (NK)-like lysis activity against YAC-1 target cells than ear and tail DEC. The NK-like lysis activity of footpad DEC was also seen in athymic nude mice (BALB/c nu/nu) but not in NK cell-defective beige mice (C57BL/6 bg/bg). The footpad DEC activity was completely abolished by in vitro and in vivo treatment with anti-Thy 1.2 or anti-asialo GM1 antibody, and VV replicated in the footpad 10(3) fold more than in the untreated group, but not by treatment with anti-Iad antibody. When footpad Thy 1.2+ asialo GM1+ DEC were adoptively transferred to the tail skin of syngeneic mice, followed by intradermal challenge of the mice with VV, viral replication in the tail skin was markedly suppressed. These results indicated that the pathogenicity of VV in the skin is affected by Thy 1.2+ asialo GM1+ DEC rather than by Ia+ LC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826826     DOI: 10.1007/bf01310766

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  16 in total

Review 1.  Role of epidermal Langerhans cells in viral infections.

Authors:  E Sprecher; Y Becker
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

2.  Natural killer cells: a primitive immune system.

Authors:  C A Janeway
Journal:  Nature       Date:  1989-09-14       Impact factor: 49.962

3.  Evolution of recurrent herpes simplex lesions. An immunohistologic study.

Authors:  A L Cunningham; R R Turner; A C Miller; M F Para; T C Merigan
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

4.  Evaluation of antiviral compounds by suppression of tail lesions in vaccinia-infected mice.

Authors:  J J Boyle; R F Haff; R C Stewart
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

5.  Role of epidermal Langerhans cells in resistance to herpes simplex virus infection.

Authors:  S Yasumoto; N Okabe; R Mori
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

6.  Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs.

Authors:  S Ikeda; T Negishi; C Nishimura
Journal:  Antiviral Res       Date:  1985-08       Impact factor: 5.970

7.  Thy-1 antigen-bearing dendritic cells populate murine epidermis.

Authors:  P R Bergstresser; R E Tigelaar; J H Dees; J W Streilein
Journal:  J Invest Dermatol       Date:  1983-09       Impact factor: 8.551

8.  Antiherpes activity of the immunomodulator OK-432, a streptococcal preparation, in immunosuppressed mice.

Authors:  S Ikeda; K Sai; C Nishimura; A Yamamoto
Journal:  Antiviral Res       Date:  1988-12-11       Impact factor: 5.970

9.  CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex.

Authors:  P Anderson; M Caligiuri; J Ritz; S F Schlossman
Journal:  Nature       Date:  1989-09-14       Impact factor: 49.962

10.  Herpes simplex virus type 1-induced interferon production and activation of natural killer cells in mice.

Authors:  H Kirchner; H Engler; C H Schröder; R Zawatzky; E Storch
Journal:  J Gen Virol       Date:  1983-02       Impact factor: 3.891

View more
  1 in total

1.  Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes.

Authors:  Geoffrey O Gillard; Maytal Bivas-Benita; Avi-Hai Hovav; Lauren E Grandpre; Michael W Panas; Michael S Seaman; Barton F Haynes; Norman L Letvin
Journal:  PLoS Pathog       Date:  2011-08-04       Impact factor: 6.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.